NCT03081858 - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

August 27, 2020

Study Completion Date

August 5, 2021

Conditions

Bladder Cancer Cell TransitionalNon-Muscle Invasive Bladder CancerBladder CancerUrinary BladderTransitional Cell Carcinoma of the BladderUrinary Bladder NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsUrinary Bladder DiseasesUrologic Diseases

Interventions

DRUG

TSD-001

Administered via intravesical instillation.

Trial Locations (5)

21076

Chesapeake Urology Associates, Hanover

29572

Carolina Urologic Research Clinic, Myrtle Beach

85741

Urological Associates of Southern Arizona, PC, Tucson

90048

Tower Urology, Los Angeles

93301

Trovare Clinical Research, Bakersfield